These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32767823)

  • 1. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis.
    Barochiner J; Martínez R
    J Clin Pharm Ther; 2020 Dec; 45(6):1244-1252. PubMed ID: 32767823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
    Baral R; White M; Vassiliou VS
    Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
    Yin J; Wang C; Song X; Li X; Miao M
    Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
    Chen C; Wang F; Chen P; Jiang J; Cui G; Zhou N; Moroni F; Moslehi JJ; Ammirati E; Wang DW
    J Am Heart Assoc; 2020 Nov; 9(21):e017736. PubMed ID: 32807002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
    Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
    Bezabih YM; Bezabih A; Alamneh E; Peterson GM; Bezabhe W
    BMC Infect Dis; 2021 Jun; 21(1):527. PubMed ID: 34090358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
    Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
    BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin system-targeting antihypertensive drugs and risk of vascular cognitive impairment: A meta-analysis.
    Zhuang S; Li J; Wang X; Wang HF; Zhang WJ; Wang HY; Xing CM
    Neurosci Lett; 2016 Feb; 615():1-8. PubMed ID: 26797651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
    Ssentongo AE; Ssentongo P; Heilbrunn ES; Lekoubou A; Du P; Liao D; Oh JS; Chinchilli VM
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33154144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.
    Hasan SS; Kow CS; Hadi MA; Zaidi STR; Merchant HA
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):571-590. PubMed ID: 32918209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension.
    Kuzeytemiz M; Tenekecioglu E
    J Investig Med; 2022 Mar; 70(3):786-791. PubMed ID: 34987107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
    Lee MMY; Docherty KF; Sattar N; Mehta N; Kalra A; Nowacki AS; Solomon SD; Vaduganathan M; Petrie MC; Jhund PS; McMurray JJV
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):165-178. PubMed ID: 33337478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis.
    Zhang G; Wu Y; Xu R; Du X
    J Med Virol; 2021 Apr; 93(4):2287-2300. PubMed ID: 33231299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
    Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
    Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
    Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
    J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension.
    Feng B; Zhang D; Wang Q; Yu F; Zou Q; Xie G; Wang R; Yang X; Chen W; Lou B; Zheng S; Chen Y
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):330-340. PubMed ID: 33835767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.